8-K: Candel Therapeutics Announces Positive Phase 3 Data and Full Year 2024 Financial Results

Candel Therapeutics reports positive data from a pivotal Phase 3 trial for CAN-2409 in prostate cancer and announces its full year 2024 financial results, highlighting a transformational year for the company.

Summary

• Candel Therapeutics announced its fourth quarter and full year 2024 financial results.
• The company reported positive topline Phase 3 data for CAN-2409 in intermediate-to-high-risk localized prostate cancer.
• CAN-2409 demonstrated a 30% reduction in the risk of prostate cancer recurrence or death compared to the placebo control arm (p=0.0155).
• 80.4% of patients in the CAN-2409 arm achieved pathological complete responses in 2-year post-treatment biopsies, compared to 63.6% in the control arm (p=0.0015).
• Positive final overall survival data was reported from a Phase 2a trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinoma (PDAC), with a median overall survival of 31.4 months in the CAN-2409 arm versus 12.5 months in the control arm.
• The company expects to report biomarker and final overall survival data from a Phase 2a trial of CAN-2409 in non-small cell lung cancer (NSCLC) in Q1 2025.
• Biomarker and initial survival data from an ongoing Phase 1b trial evaluating multiple doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG) is expected in Q4 2025.
• The company is preparing for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in Q4 2026.
• A public offering in December 2024 resulted in net proceeds of approximately $85.9 million.
• Research and development expenses were $4.8 million for the fourth quarter of 2024 and $19.3 million for the full year 2024.
• General and administrative expenses were $3.3 million for the fourth quarter of 2024 and $14.1 million for the full year 2024.
• The net loss for the fourth quarter of 2024 was $14.1 million, and the net loss for the full year 2024 was $55.2 million.
• Cash and cash equivalents as of December 31, 2024, were $102.7 million, expected to fund operations into the first quarter of 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the successful Phase 3 trial results, promising Phase 2a data, and a strengthened financial position. The company is progressing towards BLA submission and has a clear strategic direction.

Positives

• Positive Phase 3 data for CAN-2409 in prostate cancer indicates potential for regulatory approval and market entry.
• The Phase 2a trial results in pancreatic cancer demonstrate a significant improvement in overall survival, suggesting a potential new treatment option.
• The successful public offering strengthens the company's financial position, providing resources for ongoing and future clinical trials.
• The FDA has granted fast track designation for CAN-2409 for the treatment of PDAC, stage III/IV NSCLC and localized primary prostate cancer.
• The FDA has also granted orphan drug designation to CAN-2409 for the treatment of PDAC.
• The FDA granted fast track designation and orphan drug designation to CAN-3110 for the treatment of rHGG in February and May 2024, respectively.

Negatives

• The company reported a net loss of $55.2 million for the full year 2024, primarily due to the change in the fair value of the company's warrant liability.
• Research and development expenses decreased, which could potentially impact the pace of future development programs.

Risks

• The BLA submission for CAN-2409 in prostate cancer is not expected until Q4 2026, which is subject to regulatory review and potential delays.
• Clinical trials are subject to inherent risks, including the possibility of unexpected adverse events or failure to meet endpoints.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to regulatory and market risks.
• The company's cash runway is projected to last into the first quarter of 2027, requiring additional funding in the future.

Future Outlook

Candel Therapeutics plans to focus on preparing for the BLA submission for CAN-2409 in prostate cancer and continue exploring the efficacy of CAN-2409 in other indications, including pancreatic cancer and NSCLC. The company expects its current cash and cash equivalents to fund its operating plan into the first quarter of 2027.

Management Comments

• Last year was transformational for Candel, driven by our teams incredible focus and execution of the Companys key priorities, said Paul Peter Tak, MD PhD FMedSci, President and CEO of Candel.
• We delivered positive data across our platforms, including pivotal topline phase 3 data for CAN-2409 in intermediate-to-high-risk localized prostate cancer in December, which we believe shows the potential of CAN-2409, if approved, to redefine the current standard of care for patients with prostate cancer.
• We enter 2025 well-resourced with a clear direction and mandate.
• Our primary focus for the year is working toward readiness to submit CAN-2409s BLA for prostate cancer, a key opportunity to address a very significant unmet need and opportunity for value creation.

Industry Context

Candel Therapeutics is focused on developing multimodal biological immunotherapies for cancer, a growing area of interest in the biopharmaceutical industry. The positive Phase 3 data for CAN-2409 in prostate cancer positions the company to potentially compete with existing treatments and address an unmet need in the market. The company's enLIGHTEN Discovery Platform also positions them to develop novel therapies for solid tumors.

Comparison to Industry Standards

• The reported 30% reduction in the risk of prostate cancer recurrence or death with CAN-2409 compares favorably to other treatments in the intermediate-to-high-risk localized prostate cancer space, such as radical prostatectomy and radiation therapy, though direct comparisons require careful consideration of trial designs and patient populations.
• The median overall survival of 31.4 months in the CAN-2409 arm of the pancreatic cancer trial is a notable improvement compared to the 12.5 months in the control arm, and appears competitive against other therapies for borderline resectable pancreatic cancer, such as FOLFIRINOX and gemcitabine-based regimens.
• Companies like BioNTech and Moderna are also developing mRNA-based cancer vaccines, while others like Amgen and Bristol Myers Squibb are focused on checkpoint inhibitors and cell therapies, creating a competitive landscape for Candel's immunotherapeutic approaches.

Stakeholder Impact

• Shareholders will likely react positively to the positive clinical trial data and strengthened financial position.
• Employees may experience increased job security and opportunities for advancement due to the company's progress.
• Patients with prostate cancer, pancreatic cancer, and other solid tumors may benefit from the development of new treatment options.
• Suppliers and partners may see increased business opportunities as the company advances its clinical programs.
• Creditors may view the company as a lower risk due to its improved financial stability.

Next Steps

• Report final overall survival data from phase 2a clinical trial evaluating CAN-2409 in patients with NSCLC in Q1 2025.
• Report biomarker and initial overall survival data from ongoing phase 1b clinical trial evaluating multiple doses of CAN-3110 in patients with rHGG in Q4 2025.
• Prepare for Biologics License Application (BLA) for CAN-2409 in prostate cancer, with submission expected in Q4 2026.

Key Dates